

Certificate of Analysis for NR-54972

pSMART® BAC V2.0 Vector Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Non-Infectious Replicon

Catalog No. NR-54972

Product Description:

The vector for the non-infectious replicon from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: NC 045512) was designed by cloning a T7 promoter upstream of the SARS-CoV-2 insert and a poly A/HDV ribozyme and T7 terminator cassette downstream and subcloned into the pSMART® BAC V2.0 cloning vector (GenBank: EU101022). The spike (S) gene was replaced by a luciferase (Luc2) and enhanced green fluorescent protein (eGFP) fusion construct. The envelope (E) and membrane (M) genes were replaced with a neomycin resistance gene, aminoglycoside transferase. NR-54972 contains the chloramphenicol acetyltransferase gene, cat, to provide transformant selection through chloramphenicol resistance in *Escherichia coli (E. coli)* and a neomycin-selectable marker for mammalian expression. NR-54972 was produced by the inoculation of BEI Resources seed lot 70042539 into Luria-Bertani broth with chloramphenicol (12.5 μ g/mL) and incubated for 20 hours at 37°C in an aerobic atmosphere to produce this lot. The plasmid was extracted using a Plasmid *Plus* Maxi Kit (QIAGEN® 12963) and vialed in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

Lot: 70064038 Manufacturing Date: 08FEB2024

TEAT		DECLU TO
TEST	SPECIFICATIONS	RESULTS
Next-Generation DNA Sequencing	36,026 base pairs	36,024 base pairs ¹
Genotypic Analysis Sequencing of SARS-CoV-2 replicon insert (28,473 base pairs)	≥ 99% sequence identity to depositor's sequence Luc2-eGFP fusion sequence present	100% sequence identity to depositor's sequence Luc2-eGFP fusion sequence present
Antibiotic Resistance Chloramphenicol (encoded by chloramphenicol acetyltransferase gene <i>cat</i>)	cat sequence present	cat sequence present
Neomycin [encoded by aminoglycoside 3'-phosphotransferase gene <i>aph</i> (3')-II]	aph(3')-II sequence present	aph(3')-II sequence present
Concentration by Qubit Fluorometer®	≥ 2 µg/mL	0.46 μg in 50 μL/vial (9.3 μg/mL)
Amount per Vial	Report results	0.46 μg/vial
OD ₂₆₀ /OD ₂₈₀ Ratio (pre-vial)	1.7 to 2.1	1.98
Effective Bacterial Transformation Invitrogen™ MAX Efficiency™ Stbl2™ <i>E. coli</i>	≥ 50 colonies/ng	119 colonies/ng

¹The sequence was assembled pre-vial using the depositor's predicted sequence as the reference sequence. The complete plasmid sequence and map are provided on the BEI Resources webpage.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-54972

/Sonia Bjorum Brower/ Sonia Bjorum Brower

05 JUN 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898